Discovery of chemotherapy‐associated ovarian cancer antigens by interrogating memory T cells. Issue 8 (22nd October 2013)

• Record Type: Journal Article
• Authors: Paroli, Marino; Bellati, Filippo; Videtta, Melissa; Focaccetti, Chiara; Mancone, Carmine; Donato, Tiziana; Antonilli, Morena; Perniola, Giorgia; Accapezzato, Daniele; Napoletano, Chiara; Nuti, Marianna; Bartolazzi, Armando; Panici, Pierluigi Benedetti; Tripodi, Marco; Palombo, Fabio; Barnaba, Vincenzo
• Is Part Of: International journal of cancer. Volume 134:Issue 8(2014:Apr. 15)
• Page Start: 1823
• Page End: 1834
• Publication Date: 2013-10-22
• Subjects: Cancer -- Periodicals; Cancer -- Prevention -- Periodicals; 616.994
• DOI: 10.1002/ijc.28515
• Languages: English
• ISSNs: 0020-7136

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>According to the immunogenic cell death hypothesis, clinical chemotherapy treatments may result in CD8<sup>+</sup> and CD4<sup>+</sup> T‐cell responses against tumor cells. To discover chemotherapy‐associated antigens (CAAs), T cells derived from ovarian cancer (OC) patients (who had been treated with appropriate chemotherapy protocols) were interrogated with proteins isolated from primary OC cells. We screened for immunogenicity using two‐dimensional electrophoresis gel‐eluted OC proteins. Only the selected immunogenic antigens were molecularly characterized by mass‐spectrometry‐based analysis. Memory T cells that recognized antigens associated with apoptotic (but not live) OC cells were correlated with prolonged survival in response to chemotherapy, supporting the model of chemotherapy‐induced apoptosis as an adjuvant of anti‐tumor immunity. The strength of both memory CD4<sup>+</sup> and CD8<sup>+</sup> T cells producing either IFN‐γ or IL‐17 in response to apoptotic OC antigens was also significantly greater in Responders to chemotherapy than in nonresponders. Immunogenicity of some of these antigens was confirmed using recombinant proteins in an independent set of patients. The T‐cell interrogation system represents a strategy of reverse tumor immunology that proposes to identify CAAs, which may then be validated as possible prognostic tumor biomarkers or cancer vaccines.</p> </abstract>